Achievement and Maintenance of Sustained Response During the Treatment for Adolescents With Depression Study Continuation and Maintenance Therapy | Adolescent Medicine | JAMA Psychiatry | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.206.238.77. Please contact the publisher to request reinstatement.
1.
Mueller  TILeon  ADKeller  MGSolomon  DAEndicott  JCoryell  YWarshaw  MMaser  JD Recurrence after recovery from major depressive disorder during 15 years of observational follow-up.  Am J Psychiatry 1999;156 (7) 1000- 1006PubMedGoogle Scholar
2.
Emslie  GJRush  AWeinberg  WGullion  DRintelmann  JHughes  C Recurrence of major depressive disorder in hospitalized children and adolescents.  J Am Acad Child Adolesc Psychiatry 1997;36 (6) 785- 792PubMedGoogle ScholarCrossref
3.
Frank  EPrien  RFJarrett  RBKeller  MBKupfer  DJLavori  PWRush  AJWeissman  MM Conceptualization and rationale for consensus definitions of terms in major depressive disorder: remission, recovery, relapse, and recurrence.  Arch Gen Psychiatry 1991;48 (9) 851- 855PubMedGoogle ScholarCrossref
4.
 Practice parameters for the assessment and treatment of children and adolescents with depressive disorders: AACAP.  J Am Acad Child Adolesc Psychiatry 1998;37 (10) ((suppl)) 63S- 83SPubMedGoogle ScholarCrossref
5.
Park  RJGoodyer  IM Clinical guidelines for depressive disorders in childhood and adolescence.  Eur Child Adolesc Psychiatry 2000;9 (3) 147- 161PubMedGoogle ScholarCrossref
6.
American Psychiatric Association, Practice guideline for major depressive disorder in adults.  Am J Psychiatry 1993;150 (4) ((suppl)) 1- 26PubMedGoogle Scholar
7.
Depression Guideline Panel, Depression in Primary Care, Vol I: Treatment of Major Depression. Clinical Practice Guideline.  Rockville, MD US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research1993;
8.
Kutcher  S Practitioner review: the pharmacotherapy of adolescent depression.  J Child Psychol Psychiatry 1997;38 (7) 755- 767PubMedGoogle ScholarCrossref
9.
Prien  RFKocsis  JH Long-term treatment of mood disorders. Bloom  FEKupfer  DJ Psychopharmacology: The Fourth Generation of Progress. New York, NY Raven Press1995;1067- 1079Google Scholar
10.
Kroll  LHarrington  RJayson  DFraser  JGowers  S Pilot study of continuation cognitive-behavioral therapy for major depression in adolescent psychiatric patients.  J Am Acad Child Adolesc Psychiatry 1996;35 (9) 1156- 1161PubMedGoogle ScholarCrossref
11.
Emslie  GJHeiligenstein  JHHoog  SLWagner  KDFindling  RL McCracken  JTNilsson  MEJacobson  JG Fluoxetine treatment for prevention of relapse of depression in children and adolescents: a double-blind, placebo-controlled study.  J Am Acad Child Adolesc Psychiatry 2004;43 (11) 1397- 1405PubMedGoogle ScholarCrossref
12.
Poznanski  EOMokros  HB Manual for the Children's Depression Rating Scale–Revised.  Los Angeles, CA Western Psychological Services1996;
13.
Clarke  GNRohde  PLewinsohn  PMHops  HSeeley  JR Cognitive-behavioral treatment of adolescent depression: efficacy of acute group treatment and booster sessions.  J Am Acad Child Adolesc Psychiatry 1999;38 (3) 272- 279PubMedGoogle ScholarCrossref
14.
Treatment for Adolescents With Depression Study Team, Treatment for Adolescents with Depression Study (TADS): rationale, design, and methods.  J Am Acad Child Adolesc Psychiatry 2003;42 (5) 531- 542Google ScholarCrossref
15.
March  JSilva  SPetrycki  SCurry  JWells  KFairbank  JBurns  BDomino  M McNulty  SVitiello  BSevere  JTreatment for Adolescents With Depression Study (TADS) Team, Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents with Depression Study (TADS) randomized controlled trial.  JAMA 2004;292 (7) 807- 820PubMedGoogle ScholarCrossref
16.
The TADS Team, The Treatment for Adolescents with Depression Study (TADS): demographic and clinical characteristics.  J Am Acad Child Adolesc Psychiatry 2005;44 (1) 28- 40PubMedGoogle ScholarCrossref
17.
March  JSSilva  SPetrycki  SCurry  JWells  KFairbank  JBurns  BDomino  M McNulty  SVitiello  BSevere  J The Treatment for Adolescents with Depression Study (TADS): long-term effectiveness and safety outcomes.  Arch Gen Psychiatry 2007;64 (10) 1132- 1143PubMedGoogle ScholarCrossref
18.
Rush  AJKraemer  HCSackeim  HAFava  MTrivedi  MHFrank  ENinan  PTThase  MEGelenberg  AJKupfer  DJRegier  DARosenbaum  JFRay  OSchatzberg  AF Report by the ACNP Task Force on response and remission in major depressive disorder.  Neuropsychopharmacology 2006;31 (9) 1841- 1853PubMedGoogle ScholarCrossref
19.
Kaufman  JBirmaher  BBrent  DARao  UFlynn  CMoreci  PWilliamson  DRyan  ND Schedule for Affective Disorders and Schizophrenia for School-Age Children–Present and Lifetime Version (K-SADS-PL): initial reliability and validity data.  J Am Acad Child Adolesc Psychiatry 1997;36 (7) 980- 988PubMedGoogle ScholarCrossref
20.
Guy  W ECDEU Assessment Manual for Psychopharmacology. 2nd ed. Washington, DC US Government Printing Office1976;DHEW Publication ABM 76-388
21.
Curry  JRohde  PSimons  ASilva  SVitiello  BKratochvil  CReinecke  MFeeny  NWells  KPathak  SWeller  ERosenberg  DKennard  BRobins  MGinsburg  GMarch  JTADS Team, Predictors and moderators of acute treatment outcome in the Treatment for Adolescents with Depression Study (TADS).  J Am Acad Child Adolesc Psychiatry 2006;45 (12) 1427- 1439PubMedGoogle ScholarCrossref
22.
Leitenberg  HYost  LWCarroll-Wilson  M Negative cognitive errors in children.  J Consult Clin Psychol 1986;54 (4) 528- 536PubMedGoogle ScholarCrossref
23.
Brent  DABirmaher  BKolko  DBaugher  MBridge  J Subsyndromal depression in adolescents after a brief psychotherapy trial: course and outcome.  J Affect Disord 2001;63 (1-3) 51- 58PubMedGoogle ScholarCrossref
24.
Vittengl  JRClark  LADunn  TWJarrett  RB Reducing relapse and recurrence in unipolar depression: a comparative meta-analysis of cognitive-behavioral therapy's effects.  J Consult Clin Psychol 2007;75 (3) 475- 488PubMedGoogle ScholarCrossref
25.
Jacobson  NSHollon  SD Cognitive-behavior therapy versus pharmacotherapy: now that the jury's returned its verdict, it's time to present the rest of the evidence.  J Consult Clin Psychol 1996;64 (1) 74- 80PubMedGoogle ScholarCrossref
26.
Vostanis  PFeehan  CGrattan  E Two-year outcome of children treated for depression.  Eur Child Adolesc Psychiatry 1998;7 (1) 12- 18PubMedGoogle ScholarCrossref
27.
Birmaher  BBrent  DAKolko  DBaugher  MBridge  JHolder  DIyengar  SUlloa  RE Clinical outcome after short-term psychotherapy for adolescents with major depressive disorder.  Arch Gen Psychiatry 2000;57 (1) 29- 36PubMedGoogle ScholarCrossref
28.
Hollon  SDDeRubeis  RJShelton  RCAmsterdam  JDSalomon  RMO’Reardon  JPLovett  MLYoung  PRHaman  KLFreeman  BBGallop  R Prevention of relapse following cognitive therapy vs medications in moderate to severe depression.  Arch Gen Psychiatry 2005;62 (4) 417- 422PubMedGoogle ScholarCrossref
29.
Olfson  MMarcus  SCTedeschi  MWan  GJ Continuity of antidepressant treatment for adults with depression in United States.  Am J Psychiatry 2006;163 (1) 101- 108PubMedGoogle ScholarCrossref
30.
Rush  AJTrivedi  MHWisniewski  SRNierenberg  AAStewart  JWWarden  DNiederehe  GThase  MELavori  PWLebowitz  BD McGrath  PJRosenbaum  JFSackeim  HAKupfer  DJLuther  JFava  M Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.  Am J Psychiatry 2006;163 (11) 1905- 1917PubMedGoogle ScholarCrossref
31.
Schatzberg  AFRush  AFArnow  BABanks  PLCBlalock  AJBorian  FEHowland  RKlein  DNKocsis  JHKornstein  SGManber  RMarkowitz  JCMiller  INinan  PTRothbaum  BOThase  METrivedi  MHKeller  MB Chronic depression: medication (Nefazodone) or psychotherapy (CBASP) is effective when the other is not.  Arch Gen Psychiatry 2005;62 (5) 513- 520PubMedGoogle ScholarCrossref
32.
Thase  MEFriedman  ESBiggs  MMWisniewski  SRTrivedi  MHLuther  JFFava  MNierenberg  AA McGrath  PJWarden  DNiederehe  GHollon  SDRush  AJ Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report.  Am J Psychiatry 2007;164 (5) 739- 752PubMedGoogle ScholarCrossref
33.
Simons  ADMurphy  GELevine  JLWetzel  RD Cognitive therapy and pharmacotherapy of depression: sustained improvement over one year.  Arch Gen Psychiatry 1986;43 (1) 43- 48PubMedGoogle ScholarCrossref
34.
Evans  MDHollon  SDDeRubeis  JPiasecki  JMGrove  WMGarvey  MJTuason  VB Differential relapse following cognitive therapy and pharmacotherapy for depression.  Arch Gen Psychiatry 1992;49 (10) 802- 808PubMedGoogle ScholarCrossref
35.
Blackburn  IMEunson  KMBishop  S A two-year naturalistic follow-up of depressed patients treated with cognitive therapy, pharmacotherapy and a combination of both.  J Affect Disord 1986;10 (1) 67- 75PubMedGoogle ScholarCrossref
Original Article
April 2008

Achievement and Maintenance of Sustained Response During the Treatment for Adolescents With Depression Study Continuation and Maintenance Therapy

Author Affiliations

Author Affiliations: Oregon Research Institute (Dr Rohde) and University of Oregon (Dr Simons), Eugene; Duke Clinical Research Institute (Drs Silva, Tonev, and March) and Department of Psychiatry and Behavioral Sciences (Dr Curry), Duke University Medical Center, Durham, North Carolina; University of Texas Southwestern Medical Center at Dallas (Dr Kennard); National Institute of Mental Health, Bethesda, Maryland (Dr Vitiello); University of Nebraska Medical Center, Omaha (Dr Kratochvil); and Northwestern University, Evanston, Illinois (Dr Reinecke).

Arch Gen Psychiatry. 2008;65(4):447-455. doi:10.1001/archpsyc.65.4.447
Abstract

Context  The Treatment for Adolescents With Depression Study evaluated fluoxetine (FLX), cognitive behavioral therapy (CBT), and FLX/CBT combination (COMB) vs pill placebo in 439 adolescents with major depressive disorder. Treatment consisted of 3 stages: (1) acute (12 weeks), (2) continuation (6 weeks), and (3) maintenance (18 weeks).

Objective  To examine rates of achieving and maintaining sustained response during continuation and maintenance treatments.

Design  Randomized controlled trial. Response was determined by blinded independent evaluators.

Setting  Thirteen US sites.

Patients  Two hundred forty-two FLX, CBT, and COMB patients in their assigned treatment at the end of stage 1.

Interventions  Stage 2 treatment varied based on stage 1 response. Stage 3 consisted of 3 CBT and/or pharmacotherapy sessions and, if applicable, continued medication.

Main Outcome Measures  Sustained response was defined as 2 consecutive Clinical Global Impression–Improvement ratings of 1 or 2 (“full response”). Patients achieving sustained response were classified on subsequent nonresponse status.

Results  Among 95 patients (39.3%) who had not achieved sustained response by week 12 (29.1% COMB, 32.5% FLX, and 57.9% CBT), sustained response rates during stages 2 and 3 were 80.0% COMB, 61.5% FLX, and 77.3% CBT (difference not significant). Among the remaining 147 patients (60.7%) who achieved sustained response by week 12, CBT patients were more likely than FLX patients to maintain sustained response through week 36 (96.9% vs 74.1%; P = .007; 88.5% of COMB patients maintained sustained response through week 36). Total rates of sustained response by week 36 were 88.4% COMB, 82.5% FLX, and 75.0% CBT.

Conclusions  Most adolescents with depression who had not achieved sustained response during acute treatment did achieve that level of improvement during continuation and maintenance therapies. The possibility that CBT may help the subset of adolescents with depression who achieve early sustained response maintain their response warrants further investigation.

Trial Registration  clinicaltrials.gov Identifier: NCT00006286.

×